Nanexa’s clinical trial application for NEX-22 Phase I study assessed by EMA

Nanexa AB today announces that the Clinical Trial Application for the Phase I study of NEX-22 in patients with type 2 diabetes has been received and validated by the European Medicines Agency (EMA).

"EMA has now made its validation of the application as a first step and Nanexa is entering the process where we are expected to answer questions on the documentation and data that form the basis of the application. Our goal is to be able to start the Phase I study based on an approval in the first quarter of 2024, which we really look forward to", says David Westberg, CEO of Nanexa.

Datum 2023-12-20, kl 08:00
Källa MFN
100% cashback på aktiecourtage! Handla aktier på eToro och få tillbaka 100% av ditt courtage i 3 månader. Hur? Registrera dig här nu direkt för att ta del av erbjudandet.
Cashback är begränsad till högst $100. Värdet på dina investeringar kan gå upp eller ner. Du riskerar ditt kapital.